Bavarian Nordic Lands DKK 700M Government Vaccine Contract
Event summary
- Bavarian Nordic secures DKK 700M contract for MVA-BN® vaccine supply in 2026-2027.
- Majority of revenue (DKK 700M) recognized in 2027.
- Total 2026 Public Preparedness contracts now DKK 2.2B, up DKK 200M from prior guidance.
- 2026 revenue guidance unchanged at DKK 5.5B-5.7B with 28% EBITDA margin.
The big picture
This contract reinforces Bavarian Nordic's position as a key supplier in global biodefense preparedness. The deal comes amid growing government focus on pandemic readiness, with MVA-BN® being the only non-replicating mpox vaccine approved in major markets. The company's ability to secure repeat contracts highlights its strategic advantage in manufacturing and regulatory approvals.
What we're watching
- Government Demand
- Whether the pace of new government contracts will accelerate as mpox outbreaks fluctuate.
- Revenue Recognition
- How the timing of revenue recognition (majority in 2027) impacts 2026 financial performance.
- Manufacturing Scale
- Bavarian Nordic's ability to meet increased demand while maintaining production quality.
Related topics